Cambrex Completes Acquisition of Snapdragon Chemistry,
a Leader in Continuous Flow API Development Services
East Rutherford, NJ (November 21, 2022) – Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced that it has completed its acquisition of Snapdragon Chemistry, a leading US-based provider of chemical process development services to a broad range of emerging and established biopharma customers.
"I am extremely proud of what our team at Snapdragon has built over the years...With Cambrex, we have found an ideal home for our customers and employees, and I look forward to continued success as part of Cambrex." -Matt Bio, CEO of Snapdragon Chemistry
Read the Full Press Release Below